Lobbyists do not need to win the argument when they can swap the referee. Prasad’s April 2026 exit is that kind of win.
Sponsors had already gone public against his division
Reuters reported March 6, 2026, that Vinay Prasad will step down as FDA vaccines and biologics chief at end of April 2026. CNBC and Yahoo Finance coverage the same day tied the news to a string of disputes with Moderna, UniQure, and Sarepta-era gene therapy fights STAT and BioPharma Dive documented in 2025. When companies call regulatory uncertainty a market risk, their trade groups amplify it; the exit removes the named official most associated with those delays.
Makary’s framing smooths the handoff
Makary told outlets including ContagionLive that Prasad is returning to UCSF on a planned leave. That narrative gives the FDA a dignified off-ramp while giving sponsors a clean reset before the next PDUFA calendar. wbur.org’s March 10, 2026, piece still centers the same underlying fact: the controversial decisions were on vaccines and gene therapies, the two highest-lobbying lanes in biologics.
What This Actually Means
The lobby win is not a statutory change; it is personnel. The next CBER director inherits the same statutes but not the same appetite to say no in public. Investors read that as reduced tail risk.